The meeting was called to order at approximately 1:39 p.m. on Tuesday March 10, 2015.

Committee members present: Anita Steinbergh, D.O.; Margaret Huwer, Pharm.D.; Curtis Gingrich, M.D.; James Fry, PA-C; and Robert Zaayer, PA-C.

Staff members present: Sallie Debolt, and Cathy Hacker

Guests: Beth Adamson, OAPA

I. **Review of the February 10, 2015 minutes:**

Mr. Fry began the meeting by asking the members if anyone had comments on the minutes. Ms. Hacker told the members that there was a handout of the latest draft of the minutes due to requests for changes.

Dr. Steinbergh moved to approve minutes from the February 10, 2015 meeting as amended. Mr. Zaayer seconded the motion. All members voted aye. The motion carried.

II. **Formulary Review**

The committee began the meeting with the discussion of the FDA approval of Vyvanse for the treatment of binge eating. It was noted that this medication is usually used in the treatment of ADHD. Ms. Debolt stated that the current rules prohibit physicians from prescribing this medication for binge eating. She stated that if we were to add this medication to the formulary it would have to be in the CTP may not prescribe. She noted that it is currently on the formulary under amphetamines as physician initiated for the treatment of ADHD. No changes were made to the formulary.

Mr. Fry told the committee that he had a conversation with Dr. Dobrovich regarding his request for changes to IV medications on the PA formulary. He stated that Dr. Dobrovich wants to attend the April 2015 PA/Scope of Practice committee to address the committee and the Boards concerns regarding this request.

Ms. Hacker asked the committee if we could remove the changes regarding the IV medications that were previously made so that the formulary with the megace and marinol changes could be put onto the website. It was suggested that the formulary be sent to Ms. Ash to remove the unapproved changes and once that is done the updated formulary could be put onto the website.

III. **Specials services applications review**

The committee discussed the special services applications from Orthopaedic Specialists and Sports Medicine that are requesting approval of Pesanserine injections.

Dr. Steinbergh stated that this application meets the standards that have been previously approved for these injections.
Dr. Steinbergh moved to approve this request for pesanserine injection with the physician providing 100% onsite supervision, the PA would have 2 years orthopaedic experience, the physician would see the patient prior to the initial injection after the training period of the physician assistant watching the physician in performing 25 procedures then the physician watching the PA in performing 25 procedures to determine competency. Mr. Zaayer seconded the motion. All members voted aye. The motion carried.

The committee discussed the special services applications from Orthopaedic Specialists and Sports Medicine that are requesting approval of CMC thumb joint injections.

Dr. Steinbergh stated that this application meets the standards that have been previously approved for these injections.

Dr. Steinbergh moved to approve this request for CMC thumb joint injection with the physician providing 100% onsite supervision, the PA would have 2 years orthopaedic experience, the physician would see the patient prior to the initial injection after the training period of the physician assistant watching the physician in performing 25 procedures then the physician watching the PA in performing 25 procedures to determine competency. Mr. Zaayer seconded the motion. All members voted aye. The motion carried.

IV. New business

The committee discussed the email request to consider multiple sclerosis medications.

Ms. Ash had sent an email requesting that the committee consider Droxidopa, Dalfampridine, Mitoxantrone, Teriflunomide, and Interferon beta-1a.

It was noted that Droxidopa is currently on the formulary as PI, Dalfampridine is not currently listed on the formulary and will require its own class of medication, Mitoxantrone and Teriflunomide are on the formulary as CTP may not and Interferon beta-1a currently listed as PI. Ms. Huwer stated that Ampyra is a potassium channel blocker and has serious side effects. Dr. Steinbergh recommended listing it as CTP may not prescribe or tabling these medications until the committee has more information. Ms. Huwer stated that she would research these medications and the committee could discuss them next month.

Ms. Huwer moved to table the discussion on multiple sclerosis medications. Dr. Gingrich seconded the motion. All members voted aye. The motion carried.

While reviewing the formulary it was noted that opioid antagonists for addiction treatment are in the wrong category as they are prohibited by federal law. Opioid antagonists were moved to the CTP may not prescribe category.

Dr. Steinbergh moved to approve moving opioid antagonists to the CTP may not prescribe category. Mr. Zaayer seconded the motion. All members voted aye. The motion carried.

The Physician Assistant Policy Committee meeting was adjourned by Mr. Fry at approximately 2:22 p.m. on Tuesday, March 10, 2015.

I hereby attest that these are the true and accurate minutes of the Physician Assistant Policy Committee of the State Medical Board of Ohio, meeting on March 10, 2015.

----------------------------------
James Fry, PA-C, Chair, PAPC